Mersana Therapeutics Receives Buy Rating from William Blair

Mersana Therapeutics (MRSN) has received a Buy rating from William Blair analyst Andy Hsieh. The company's shares opened at $5.26. Hsieh is a 4-star analyst with a 6.5% average return and 44.90% success rate. The analyst consensus on MRSN is a Strong Buy with an average price target of $40.75. The company reported a quarterly revenue of $2.75 million and a GAAP net loss of $24.12 million for Q1.

Mersana Therapeutics Inc. (MRSN) reported its Q1 2025 earnings on July 2, 2025, with the company's shares opening at $5.26. The company reported a quarterly revenue of $2.75 million and a GAAP net loss of $24.12 million [1].

Analysts from William Blair have given Mersana Therapeutics a Buy rating, with a target price of $40.75. The analyst consensus on MRSN remains a Strong Buy, with an average price target of $40.75 [2].

In Q1 2025, Mersana Therapeutics reported a quarterly adjusted loss of $4.87 per share, higher than the same quarter last year when the company reported EPS of $-5.00. Revenue rose 33.3% to $3.06 million from a year ago, but it fell short of analyst expectations of $6.36 million [1].

The company's shares have fallen by 18.0% this quarter and lost 83.0% so far this year. The mean earnings estimate of analysts had risen by about 20.6% in the last three months, with no revisions in the last 30 days [1].

Mersana Therapeutics' earnings are expected to decrease from ($0.62) per share to ($0.67) per share in the next year [1]. The company's upcoming earnings date is scheduled for Thursday, May 8, 2025 [1].

References:

[1] https://www.marketbeat.com/stocks/NASDAQ/MRSN/earnings/
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3U50ZY:0-mersana-therapeutics-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/